Targeting cytomegalovirus during ulcerative colitis flare-ups

Area of Science:

• Gastroenterology
• Virology
• Immunology

Background:

• Human cytomegalovirus (CMV) is a significant opportunistic pathogen, particularly in immunocompromised individuals.
• CMV reactivation is frequently observed in inflammatory bowel disease (IBD) patients, especially those with ulcerative colitis (UC) undergoing immunosuppressive therapy.
• The established relationship between CMV reactivation and UC exacerbation necessitates defined therapeutic strategies.

Purpose of the Study:

• To review current therapeutic strategies for managing CMV infection in ulcerative colitis patients.
• To highlight recent findings on the efficacy of antiviral therapy in specific UC patient subgroups.

Main Methods:

• Literature review of studies investigating CMV infection in UC patients.
• Analysis of recent findings suggesting benefits of antiviral therapy based on histological confirmation or quantitative PCR of CMV load.

Main Results:

• Antiviral therapy shows potential benefit in UC patients with histologically proven CMV colitis.
• A high colonic CMV load, as detected by quantitative PCR, may also indicate a need for antiviral treatment.

Conclusions:

• Further prospective studies are required to establish definitive guidelines for antiviral therapy initiation in UC patients with CMV infection.
• Optimal control of mucosal inflammation remains the cornerstone of managing CMV infection in UC patients.